secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-050739
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q4 net sales $87M (+17% YoY); FY $321M (+20%); guides 2024 low double-digit growth
--------------------------------------------------------------------------------

- Net sales Q4 $87M, FY $321M, up 17% and 20% YoY respectively.
- GAAP net income Q4 $53M (incl. $40M one-time tax benefit), FY $58M.
- Adjusted EBITDA Q4 $21M, margin 24%.
- 2024 guidance: low double-digit net sales growth, adjusted EBITDA margin >20%.
- Launched EPIEFFECT wound care product; completed debt refinancing Jan 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/0001193125-24-050739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000119312524050739/d801521d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-050739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer